Novartis
Highly Engaged Employees
Manufacturing · Switzerland · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Lichtstrasse 35, Basel, Basel-City, 4056...Phone Number
+41 613241111Website
novartis.comRevenue
$56.7 BillionStock Symbol
NVSIndustry
About Novartis
Novartis Org Chart
Is Novartis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Novartis
Website visits: Recent activity has been detected on your website
Novartis, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Novartis is spiking on competitors!
Earning: See what the market has to say on Novartis recently announced quarterly report
Click to see if Novartis had a recent Job posting/layoffs
Product Launch: Get notified when Novartis launches new products
Check if Novartis has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Novartis has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Novartis
Compare insights from companies similar to Novartis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Novartis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novartis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novartis.
Novartis Tech Stack
A closer look at the technologies used by Novartis
Most Recent Scoops
Novartis News & Media
Novartis doubles down on molecular glue strategy - STAT News
Today's biotech news includes seniors' drug costs rise sharply, Enliven's leukemia drug, and Novartis doubling down on molecular glueNovartis $12bn bet on Avidity well placed after mid-stage FSHD win
Novartis-owned Avidity Biosciences is currently evaluating del-brax in a recruiting Phase III study in FSHD.Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Ad hoc announcement pursuant to Art. 53 LRNovartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (C
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novarti... Read More